NeuraWell is a clinical-stage research and development company focused on developing safe and effective medicines for the potential treatment of various CNS disorders.  These target disorders include a primary focus on major depressive disorder (MDD), treatment-resistant depression (TRD), and treatment-resistant anxiety. Additional future development opportunities include neurological conditions such as Parkinson’s disease and seizure disorders.

Our mission is to offer CNS treatments that reliably deliver meaningful therapeutic responses with enhanced safety,  to fill an unmet need where other treatments have failed.